GLPwatch
Pemvidutide
Pipeline · GLP-1 and glucagon receptor dual agonist
Last updated 2026-05-28Pemvidutide is an experimental drug that works by activating both the GLP-1 and glucagon receptors, which are involved in regulating blood sugar and appetite. It is being developed as a potential treatment for obesity and related conditions, though it has not yet been approved for any use.
AI summary of the sources below.
| Mechanism | GLP-1 and glucagon receptor dual agonist Acts on the GLP-1 and glucagon receptors, which affect blood sugar, appetite, and how the body uses energy. |
|---|---|
| Status | Pipeline |
| Branded products | — (none approved) |
| Manufacturer(s) | altimmune |
How Pemvidutide connects
Trials (5)
- Pemvidutide (ALT-801) DDI Study in Healthy Volunteers
- ALT-801 (Pemvidutide) in Healthy Overweight and Obese Volunteers to Study Safety and Tolerability
- RESTORE TRIAL: A Phase 2 Study Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol-Associated Liver Disease (ALD)
- IMPACT TRIAL: Efficacy and Safety of Pemvidutide in Subjects With Nonalcoholic Steatohepatitis (NASH)
- RECLAIM STUDY: A Phase 2 Evaluating the Efficacy and Safety of Pemvidutide in the Treatment of Alcohol Use Disorder (AUD) in Subjects With Obesity or Overweight
Top research (4)
- Effect of pemvidutide, a GLP-1/glucagon dual receptor agonist, on MASLD: A randomized, double-blind, placebo-controlled study.
- Safety and efficacy of weekly pemvidutide versus placebo for metabolic dysfunction-associated steatohepatitis (IMPACT): 24-week results from a multicentre, randomised, double-blind, phase 2b study.
- Safety and efficacy of 24 weeks of pemvidutide in metabolic dysfunction-associated steatotic liver disease: A randomized, controlled clinical trial.
- The dual GLP-1-glucagon agonist pemvidutide in MASH: a phase 2b trial.